Cargando…

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis

OBJECTIVES: To characterize the 10 year relationship between anti-transcriptional intermediary factor 1 antibody (anti-TIF1-Ab) positivity and cancer onset in a large UK-based adult DM cohort. METHODS: Data from anti-TIF1-Ab-positive/-negative adults with verified diagnoses of DM from the UK Myositi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oldroyd, Alexander, Sergeant, Jamie C, New, Paul, McHugh, Neil J, Betteridge, Zoe, Lamb, Janine A, Ollier, William E, Cooper, Robert G, Chinoy, Hector
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434375/ https://www.ncbi.nlm.nih.gov/pubmed/30535395 http://dx.doi.org/10.1093/rheumatology/key357

Ejemplares similares

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply
por: Oldroyd, Alexander, et al.
Publicado: (2019)

Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies
por: Parkes, Joanna E., et al.
Publicado: (2016)

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis
por: Parkes, Joanna E., et al.
Publicado: (2018)

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis
por: Gunawardena, H, et al.
Publicado: (2009)

Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset
por: Tansley, Sarah L., et al.
Publicado: (2014)

Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis
por: Satoh, Minoru, et al.
Publicado: (2012)

Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy
por: Chinoy, Hector, et al.
Publicado: (2012)

Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2020)

Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis
por: Megremis, Spyridon, et al.
Publicado: (2021)

The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort
por: Parker, Matthew J S, et al.
Publicado: (2019)

8.4 Novel autoantibodies targeting a p140 protein are a major autoantigen system in juvenile dermatomyositis and a marker of calcinosis
por: Gunawardena, H, et al.
Publicado: (2008)

Recent advances in the immunogenetics of idiopathic inflammatory myopathy
por: Chinoy, Hector, et al.
Publicado: (2011)

Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies
por: Mahler, Michael, et al.
Publicado: (2019)

Anti-transcription Intermediary Factor1γ-antibody-positive Dermatomyositis Complicated by Dysphagia
por: Kurushima, Shota, et al.
Publicado: (2017)

Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study
por: Parker, Matthew J S, et al.
Publicado: (2018)

SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report
por: Arnon, Johnathan, et al.
Publicado: (2021)

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer
por: Betteridge, Zoe E., et al.
Publicado: (2018)

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis
por: Betteridge, Zoe, et al.
Publicado: (2020)

The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients
por: Tansley, Sarah L, et al.
Publicado: (2020)

Lung adenocarcinoma and anti‐transcriptional intermediary factor 1‐gamma positive dermatomyositis complicated with spontaneous oesophageal rupture
por: Saraya, Takeshi, et al.
Publicado: (2019)

Small cell lung cancer and interstitial pneumonia associated with anti‐transcriptional intermediary factor‐1γ‐positive dermatomyositis
por: Kato, Toshio, et al.
Publicado: (2019)

Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis
por: Zhang, Suo, et al.
Publicado: (2022)

A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients
por: Sumazaki, Makoto, et al.
Publicado: (2020)

Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer
por: Sato, Yuki, et al.
Publicado: (2022)

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study
por: Tansley, Sarah L, et al.
Publicado: (2014)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy
por: Aritomi, Takafumi, et al.
Publicado: (2018)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
por: Kessler, Alaina J., et al.
Publicado: (2023)

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
por: Betteridge, Zoe E, et al.
Publicado: (2011)

My-Lupus: A case of anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis overlapping with discoid lupus erythematosus in an adult patient
por: Toker, Michelle, et al.
Publicado: (2023)

Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis
por: Rothwell, Simon, et al.
Publicado: (2019)

Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature
por: Ono, Ryohei, et al.
Publicado: (2021)

The EuroMyositis registry: an international collaborative tool to facilitate myositis research
por: Lilleker, James B, et al.
Publicado: (2018)

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity
por: Tansley, Sarah L, et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report
por: Kim, Yoonjoo, et al.
Publicado: (2022)

Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods – a qualitative study
por: Oldroyd, Alexander, et al.
Publicado: (2020)

Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?
por: Tansley, Sarah L, et al.
Publicado: (2013)

The Intermediary Metabolism of Pyrene
por: Harper, K. H.
Publicado: (1958)

Intermediary metabolism of the lung.
por: Fisher, A B
Publicado: (1984)

In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
por: Chinoy, Hector, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_442ac0akkmn09rr9rngqcvi4rl